Chemed shares fall as Medicare cap concerns overshadow earnings beat

Published 26/02/2025, 22:58
Chemed shares fall as Medicare cap concerns overshadow earnings beat

CINCINNATI - Chemed Corporation (NYSE:CHE) reported fourth-quarter earnings that beat analyst expectations, but shares tumbled 4.4% as investors focused on concerns about Medicare cap billing limitations for its VITAS hospice business.

The healthcare and plumbing services company posted adjusted earnings per share of $6.83, surpassing the analyst consensus of $6.78. Revenue rose 9.2% YoY to $640 million, also topping estimates of $636.1 million.

Chemed’s VITAS hospice segment saw strong growth, with revenue increasing 17.4% to $411 million. However, the company flagged that four of its 34 Medicare provider numbers have a trailing 12-month Medicare cap billing limitation totaling $9.6 million.

"The 60-basis point average differential between the reimbursement rate increase and the Medicare Cap increase has reduced cushion in our programs for both the trailing 12-months and our projected fiscal year 2025," Chemed stated in its earnings release.

For 2025, Chemed forecasts adjusted earnings per share of $24.95 to $25.45, compared to analyst expectations of $24.89. The company estimates Medicare cap billing limitations of $9.5 million for calendar year 2025.

The Roto-Rooter plumbing segment saw revenue decline 2.9% to $229 million in Q4, with adjusted EBITDA falling 7.2% to $60.3 million.

"We expect Roto-Rooter’s revenue and associated income to accelerate during the year, as management’s business improvement initiatives continue to build momentum," said Kevin McNamara, Chemed’s CEO.

Chemed ended the quarter with $178.4 million in cash and no debt. The company repurchased 388,235 shares for $212.8 million during Q4 at an average cost of $548.13 per share.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.